176 related articles for article (PubMed ID: 21900519)
41. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common
Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684
[TBL] [Abstract][Full Text] [Related]
42. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
[TBL] [Abstract][Full Text] [Related]
43. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Castanheira M; Messer SA; Rhomberg PR; Dietrich RR; Jones RN; Pfaller MA
Mycopathologia; 2014 Aug; 178(1-2):1-9. PubMed ID: 24952015
[TBL] [Abstract][Full Text] [Related]
44. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
45. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
[No Abstract] [Full Text] [Related]
46. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
47. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
48. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
49. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
[TBL] [Abstract][Full Text] [Related]
50. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
[TBL] [Abstract][Full Text] [Related]
51. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.
Pfaller MA; Moet GJ; Messer SA; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Feb; 55(2):561-6. PubMed ID: 21115790
[TBL] [Abstract][Full Text] [Related]
52. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
53. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
[TBL] [Abstract][Full Text] [Related]
54. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW
Drug Resist Updat; 2013 Dec; 16(6):81-95. PubMed ID: 24618110
[TBL] [Abstract][Full Text] [Related]
55. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
[TBL] [Abstract][Full Text] [Related]
56. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
[TBL] [Abstract][Full Text] [Related]
57. Outbreak of Candida auris in Spain: A comparison of antifungal activity by three methods with published data.
Ruiz-Gaitán AC; Cantón E; Fernández-Rivero ME; Ramírez P; Pemán J
Int J Antimicrob Agents; 2019 May; 53(5):541-546. PubMed ID: 30769198
[TBL] [Abstract][Full Text] [Related]
58. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
59. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
60. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
Thierry G; Morio F; Le Pape P; Gay-Andrieu F; Barre O; Miegeville M
Pathol Biol (Paris); 2011 Feb; 59(1):52-6. PubMed ID: 20832195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
